



Page 1 of 9

Safety Data Sheet

Sections 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

SDS Fidaxomicin vers 8-2024

1. Identification of the Substance and the Manufacturer

Fidaxomicin

1.1. Product identifiers

| | July | 2 | | | | | |
|--------------------------|---|----------------|--------------------|----------|--------------------|--------------|--|
| Product name | <u>Fidaxomicin</u> A | | Formula | | C52H74Cl2O18 | | |
| Product Code | FID-001 | | Molecular weight | | 1058.0 g/mol | | |
| <u>CAS</u> | <u>873857-62-6</u> | | Mixture? | | Substance | | |
| <u>ECHA</u> | <u>692-555-6</u> ∂ | | <u>PUBCHEM</u> ⁄ 🖯 | | <u>10034073</u> | | |
| <u>Drug bank</u> | <u>drugs/DB08874</u> | | <u>RTECS</u> | | Not Listed 8-2024 | | |
| Comptox EPA | <u>DTXSID901016415</u> | | <u>CHEBI</u> | | <u>CHEBI:68590</u> | A | |
| | Dificid | Clostomicin B1 | lip | iarmicin | lipiarmycin A3 | tiacumicin B | |
| Synonyms and other names | [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate | | | | | | |
| Source | From: Dactylosporangium aurantiacum Version Date 26 September, 2024 | |)24 | | | | |

(an Actinobacterium) (ersion Dure)

| 1.2. Interview uses of the Substance who uses advised ugainst | | | |
|---|------------------------------|----------|-------------------------------|
| 1.2.1. Intended use: | | 1.2.2. | Uses advised against: |
| Research and development. | Manufacturing of substances. | Not a d | rug, |
| Laboratory reagent. | To be used by professionals | Not a fe | ood additive |
| Reference material. | only | Not to k | be used in humans or animals. |

1.3. Contacts

1.3.1. Details of the supplier of the SDS

| FERMENTEK ltd | Tel: +972 2 585 | 3953 |
|----------------------------|-----------------|-------------------------|
| 4 Yatziv street, POB 47120 | Fax: +972 2 58 | 53943 |
| Jerusalem 97800, | eMail: | Fermentek@Fermentek.com |
| Israel | | Safety@Fermentek.com |
| | Website: | Fermentek.com |

This company is the manufacturer of the product and the supplier of the safety data sheet

1.3.2. Emergency Telephone number

For chemical emergency spill, leak, fire, exposure, or accident calls CHEMTREC day or night: Within USA and Canada: 1-800-424-9300. Outside USA and Canada: +1 703-527-3887







Page 2 of 9

Safety Data Sheet **Fidaxomicin**

Sections 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

SDS Fidaxomicin vers 8-2024

2. Hazards' identification.

2.1. Classification of the Substance .

To our judgement, hazards of this substance have not been thoroughly investigated Other authors have classified this substance as H300, H310, H330 (Fatal if swallowed, inhaled or in contact with skin, and H350 may cause cancer. To our opinion, these claims are neither proven experimentally, nor based on available literature 2.1.1. GHS Classification: According to EU Reg. 1272/2008 and US OSHA 1910.1200) Category 4 H302 Harmful if swallowed (based on estimate) Accute toxicity: Oral 2.2. GHS Label elements, including precautionary statements } Signal word: {Warning} Pictogram: { 2.2.1. 2.2.2. Hazard Statements H302 Harmful if swallowed 2.2.3. **GHS** Precautionary Statements P203 Obtain, read and follow all safety instructions before use. P261 Avoid breathing dust or mist. P264 Wash {hands} thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection 2.2.4. **GHS Response Phrases:** IF SWALLOWED, Rinse mouth. Call a POISON CENTER/doctor if you P330; P301+P312 feel unwell. Composition/information on ingredients 3. Substance

| Substance | |
|--------------------|----------------|
| Substance Name: | Fidaxomicin |
| Concentration | <=100% |
| CAS Registry#: | 873857-62-6 |
| <i>EC#</i> : | 692-555-6 |
| Molecular Formula: | C52H74Cl2O18 |
| Molecular Weight: | 1058.0 g/mol |
| Classification | Acc 0:4 (H302) |







Safety Fidaxomicin Data Sheet

Sections 4 5 6 7 8 9 10 11 12 13 14 15 16 1 2 3

SDS Fidaxomicin vers 8-2024


Page 3 of 9

| ure? | Substance |
|-------------------------------|---|
| First Aid Measure | s. |
| Description of First A | Aid Measures. |
| ral advice: | First-aiders need to protect themselves. If medical attention is required, show this safety data sheet to the doctor in attendance. |
| tion: | <i>If swallowed: give water to drink (two glasses at most). Seek medical advice immediately.</i> |
| Most important symp | toms and effects, both acute and delayed |
| ral symptoms | See section 11 |
| Indication of any imm | nediate medical attention and special treatment needed |
| to physicians | No data available |
| 5. Fire-fighting measures. | |
| Extinguishing media | |
| ble extinguishing media | Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. |
| itable extinguishing media | None known |
| Other information | |
| rdous combustion products | Carbon oxides, Nitrogene oxides, C52H74Cl2O18 |
| e for firefighters | Wear self-contained breathing apparatus for fire fighting if necessary. Wear protective suit. |
| | First Aid Measure Description of First A ral advice: tion: Most important symp ral symptoms Indication of any imp to physicians Fire-fighting meas Extinguishing media ble extinguishing media ble extinguishing media other information rdous combustion products |

6. Accidental release measures

6.1. Personal precautions, protective equipment, and emergency procedures

| Personal precautions | Use personal protective equipment as required. Keep people away from and upwind of spill/leak. |
|--------------------------------|--|
| 6.2. Environmental precautions | |
| Environmental precautions | Prevent further leakage or spillage if safe to do so. Prevent product |



from entering drains.









SDS Fidaxomicin vers 8-2024

Page 4 of 9

6.3. Methods and material for containment and cleaning up

| | pill for later disposal. |
|---------------------|--|
| combust and vert | p should be dealt with only by qualified personnel familiar with rific substance. Cover liquid spill with sand, earth or other non- tible absorbent material (e.g., sand, earth, diatomaceous earth, miculite). Cover the powder spill with a plastic sheet or tarp to e spreading. Sweep up and shovel into suitable containers for l. |

7. Handling and storage

7.1. Precautions for safe handling

| Advice on safe handling:Avoid contact with skin, eyes or clothing. Use personal pro equipment as required. Wash contaminated clothing before breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink when using this product. |
|---|
|---|

7.2. Conditions for safe storage, including any incompatibilities

| Storage Conditions: | Keep container tightly closed in a dry and well-ventilated place. Keep out of the reach of children. Store at -20 °C. |
|-------------------------|---|
| Suitable packaging | Must only be kept in original packaging. |
| Incompatible materials: | None known based on information available. |
| 9 Eurocumo Contr | als/Dansangl Protection |

8. Exposure Controls/Personal Protection

Attiention:

Usually, the product of concern would be present at the intended workplace in miniscule amounts, while surrounded by considerable amounts of other flammable, toxic or otherwise hazardous substances. Therefore, the employer/user should perform a risk assessment prior to the use of this product.

The type of protective equipment must be selected based on the amount and concentration of all dangerous materials being used in the workplace.

All recommendations included in this document are advisory in nature

8.1. Control parameters

Control parameters

Components with workplace control parameters









SDS Fidaxomicin vers 8-2024

Page 5 of 9

8.2. Exposure controls

| Appropriate engineering controls | Showers, Eyewash stations, Ventilation systems Avoid contact with skin, eyes, and clothing. |
|----------------------------------|---|
| | Wash hands before breaks and immediately after handling the product. Use fume-hood for routine work. |
| 9.2 Demonral protective | aguinmont |

8.3. Personal protective equipment

[PPE=Personal Protection Equipment]

| PPE: Respiratory protection | Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). |
|-----------------------------------|---|
| PPE: Hand Protection: | Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal techniques to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices, and wash and dry hands |
| PPE: Eye Protection: | Use a face shield and safety glasses. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166 (EU) |
| PPE: Skin and Body Protection: | Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of Regulation (EU) 2016/425 and the standard EN 374 derived from it. |

9. Physical and chemical properties

The information given here does not purport specification of warranty of any kind. It is designed only as guidance for safe handling, use, processing, storage, transportation, disposal, and release and is not to be considered a warranty or quality specification.

9.1. Physical/chemical properties

| Physical State at room temperature | Solid |
|---------------------------------------|---------------------------|
| Appearance | White to Off-White powder |
| No further safety relevant data | are available |









SDS Fidaxomicin vers 8-2024

Page 6 of 9

10. Stability and reactivity

| Reactivity: | No information available. | |
|------------------------------------|------------------------------------|--|
| Chemical stability: | Stable under normal conditions. | |
| Conditions to avoid | Heat, flames and sparks. Sunlight. | |
| Incompatible materials | Strong reducers and exidizers | |
| Possibility of hazardous reactions | None under normal processing | |
| Hazardous combustion products | See section 5 | |

11. Toxicological information

11.1. Information on toxicological effects

To the best of our knowledge, the toxicological effects of this product have not been thoroughly studied yet. *11.1.1.* Acute Toxicity

| Acute toxicity: | ▶Estimate ◀ Oral, Mouse, LD50>1500mg/kg |
|--|--|
| | Intravenous, Rat, LD50=200 mg/kg |
| | <i>Oral</i> , <i>Rat</i> , <i>LD50>1000 mg/kg</i> |
| | No other acute toxicity available. |
| Skin corrosion/irritation: | No data available |
| Serious eye damage/eye irritation: | No data available |
| Respiratory or skin sensitization/corrosion: | No data available |
| 11.1.2. Chronic toxicity | |

11.1.2. Chronic toxicity

| Chronic toxicity | No data available | |
|--|-----------------------------|--|
| 11.1.3. CRM (Carcinogene, Muta | gene, Reproductive hazards) | |
| Germ cell mutagenicity: | No data available | |
| Carcinogenicity: | Not classified by IARC | |
| <i>Reproductive toxicity /</i> <i>Teratogenicity:</i> | No data available | |

11.2. Additional information

| RTECS number | Not Listed 8-2024 |
|------------------|-------------------|
| General symptoms | No data available |

12. Ecological Information

Eco-Toxicity

No data available







Safety Data Sheet

Sections 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

SDS Fidaxomicin vers 8-2024

Fidaxomicin

Page 7 of 9

| Other adverse effects | | No data available | | | |
|--|---------------|---|---------------------------------|---------------------------------|---------------------------------|
| 13. Disposal Considerat | | sal Consideration | ions | | |
| 13.1. Waste treatment metho | | treatment method | S | | |
| Waste Disposal | | Dispose of in accordance with local regulations | | | |
| Contaminated packaging | | Dispose of as unused product | | | |
| 14. Transport information | | | n | | |
| 14.1. UN Number, Proper Shipping Name, Transport Hazard Class, packing group | | | acking group | | |
| | | IATA | IMDG | ADR/RID | US/DOT |
| UN N Prope | lumber, er | Not classified Not regulated | Not classified Not regulated | Not classified Not regulated | Not classified Not regulated |

| Proper shipment name | Not regulated (Fidaxomicin) |
|---|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Transport hazard Class, Packing group | Not hazardous for transport | Not hazardous for transport | Not hazardous for transport | Not hazardous for transport |
| Comments | | Not marine polutant | | |

15. Regulatory information

15.1. Safety, health, and environmental regulations/legislation

| USA EPA / TSCAThis product is not listed on the USA EPA TSCA (it is for research)EU ECHA StatusThis product is registered with the EU ECHA, Number 692-555-6 REACH: Neither Registered nor PreRegistered. ANNEX III (criteria for 1 - 10 tonne registered substances): Not Listed | | |
|---|----------------|---|
| REACH: Neither Registered nor PreRegistered. | USA EPA / TSCA | This product is not listed on the USA EPA TSCA (it is for research) |
| | EU ECHA Status | REACH: Neither Registered nor PreRegistered. |

16. Other information

16.1. Version information

Version date:8-2024 Toxicity revised. Not hazardous for transport. No reprotox.

16.2. Department issuing this SDS

Quality systems and regulatory affairs

16.3. General Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication.

The information given here is designed only as guidance for safe handling, use, processing, storage, transportation, disposal, and release and **is not to be considered a warranty or quality specification**.







Safety Data Sheet

Sections 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

SDS Fidaxomicin vers 8-2024

Page 8 of 9

The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless explicitly specified in the text.

16.4. The users'/employers' responsibility:

Fidaxomicin

Usually, the product of concern would be present at the intended workplace in miniscule amounts, while surrounded by considerable amounts of other flammable, toxic or otherwise hazardous substances.

Therefore, the employer/user should perform a risk assessment by prior to the use of this product. The type of protective equipment must be selected based on the amount and concentration of all dangerous materials being used in the workplace.

All recommendations included in this document are advisory in nature.

16.5. No ©copyright



Fermentek does not claim © copyright on this document.

Fermentek believes that no one can claim copyright on an SDS. This sort of document is but a compendium of common knowledge and published facts.

Fermentek explicitly releases this document into the public domain.

16.6. End of SDS









SDS Fidaxomicin vers 8-2024

Page 9 of 9

16.7. Appendix A : Abbreviations and acronyms:

| | This symbol means, the text looking like a hyperlink, is a clickable link indeed. Of course, these are only active on glass screens, not on paper. |
|--------------------|--|
| | "From" means the compound was extracted from biomass, whether algal, fungal, microbial or plant |
| Enorm (Swith stic | material |
| From /Synthetic | "Synthetic" means this compound has been manufactured by chemical conversion of another compound. |
| /Semisynthetic | Often, certain product is made by the method of microbial fermentation, purified, and then chemically |
| | converted into another compound. It may be called "semisynthetic". |
| | Substance means a single compound., |
| Mixture/Substance/ | Mixture means there are two or more pure substances mixed purposely. |
| Complex | Complex is a mixture of two or more substances which naturally occur together and are sold |
| | unseparated |
| Acute Tox.: | Acute toxicity |
| CAS: | Chemical Abstracts Service |
| ChEBI | Chemical Entities of Biological Interest |
| Comptox | CompTox Chemicals Dashboard Resource Hub (EPA) |
| DOT: | US Department of Transportation |
| ECHA | European Chemicals Agency |
| EINECS: | European Inventory of Existing Commercial Chemical Substances |
| EPA | United States Environmental Protection Agency |
| Eye Dam.: | Serious eye damage/eye irritation |
| HSDB | Hazardous Substances Data Bank |
| HMIS: | Hazardous Materials Identification System (USA) |
| IATA: | International Air Transport Association |
| IMDG: | International Maritime Code for Dangerous Goods |
| LC50: | Lethal concentration, Median |
| LD50: | Lethal dose, Median |
| LDL0 | Letal dose, leatst published |
| NDG | Not dangerous goods (for transport) |
| NFPA: | National Fire Protection Association USA |
| NIOSH: | National Institute for Occupational Safety |
| NOAEL | No-Observed-Adverse-Effects-Level. Highest dose which yelded no results at toxisity test |
| OSHA: | Occupational Safety & Health |
| PBT: | Persistent, Bioaccumulative, and Toxic |
| PEL: | Permissible Exposure Limit |
| PubChem | An open chemistry database at the National Institutes of Health (NIH). " |
| REL: | Recommended Exposure Limit |
| Repr.: | Reproductive toxicity, incl. hazards to reproductive systems, and pregnancy and the offspring. |
| RTECS: | Registry of Toxic Effects of Chemical Substances. Not free. |
| Skin Irrit: | Skin corrosion/irritation |
| STOT/SE | Specific target organ toxicity/Single exposure |
| STOT/RE | Specific target organ toxicity/Repeated exposure |
| T3DB | Toxin and Toxin Target Database |
| TDL0 | Toxic dose, least published |

